Cetuxibab to Reduce Circulating Tumor Cells in Early Stage NSCLC

Stopped One of the participating specialties has decided to no longer cooperate in this research

Conditions

• Lung Cancer
• Surgery
• Circulating Tumor Cell

Interventions

• DRUG: Cetuximab

Sponsor

The Netherlands Cancer Institute

Collaborators

• [object Object]